Thiomyristoyl

Catalog No.S8245 Synonyms: TM

For research use only.

Thiomyristoyl (TM) is a potent and specific SIRT2 inhibitor with an IC50 of 28 nM. It inhibits SIRT1 with an IC50 value of 98 μM and does not inhibit SIRT3 even at 200 μM.

Thiomyristoyl Chemical Structure

CAS No. 1429749-41-6

Selleck's Thiomyristoyl has been cited by 3 Publications

Purity & Quality Control

Choose Selective Sirtuin Inhibitors

Other Sirtuin Products

Biological Activity

Description Thiomyristoyl (TM) is a potent and specific SIRT2 inhibitor with an IC50 of 28 nM. It inhibits SIRT1 with an IC50 value of 98 μM and does not inhibit SIRT3 even at 200 μM.
Targets
SIRT2 [1]
(Cell-free assay)
28 nM
In vitro

Thiomyristoyl(TM) is a highly selective SIRT2 inhibitor. It cannot efficiently inhibit SIRT3, SIRT5, SIRT6, or SIRT7. In vitro, it shows great inhibition of cell viability and its cytotoxicity is relatively selective toward cancer cells. TM decreases c-Myc oncoprotein level in cancer cells, the ability of TM to decrease c-Myc abundance in different cell lines correlates with the sensitivity of the cell lines to TM[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BxPC3 MkfLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4K2TFczKGi{cx?= MnfyS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gRphRSzNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTldk1DdHWnIHHzd4F6NCCJSUWwQVE{NjQQvF2= NIHO[|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEm4OlA3Oid-M{C5PFYxPjJ:L3G+
MDA-MB-468 M2HxO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHjR[Zo4OiCqcoO= NXHzT4ZDT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWJtfWViYYPzZZktKEeLNUC9NVUvP87:TR?= MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODl6NkC2Nkc,OzB7OE[wOlI9N2F-
NCI-H23 MlPiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MV:3NkBpenN? MXXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDJ|IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuSmy3ZTDhd5NigSxiR1m1NF0yPi52zszN NXjhenk6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5PFYxPjJpPkOwPVg3ODZ{PD;hQi=>
HCT116 MmjDSpVv[3Srb36gZZN{[Xl? MYO1JIRigXN? M2HIfGlvcGmkaYTpc44hd2ZiYX7jbI9z[WenLXnu[IVx\W6mZX70JINmdGxiZ4Lve5RpKGmwIHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3;sc456KG[xcn3heIlwdiCrbnP1ZoF1\WRiZn;yJFUh\GG7czDmc4xtd3enZDDifUBkd22yb4Xu[EBz\S2jZHTpeIlwdiCjbnSgcYVie3W{ZXSgZYZ1\XJiOTD0c{AyOSCmYYnzJIJ6KG6rdILvJIJtfWVidHX0doF7d2yrdX2gZ4htd3KrZHWtZoF{\WRic3;meEBi\2G{IHPvcI9vgSxiR1m1NF0yPi55zszN NV\OWWRDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5PFYxPjJpPkOwPVg3ODZ{PD;hQi=>
A549 MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MU[3NkBpenN? NWLiUlQyT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUKudXWgZZN{[XluIFfJOVA:OTdwM988US=> NH7jWXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEm4OlA3Oid-M{C5PFYxPjJ:L3G+
SW948 NY[1XXZmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mm\4O|IhcHK| NHjqd3FIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUXzl2ODDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUKudXWgZZN{[XluIFfJOVA:OTlwMt88US=> M4CyTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUi2NFYzLz5|MEm4OlA3OjxxYU6=
MCF7 MkXhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXrMenQ2PzJiaILz NXnZWpk4T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUOINzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUKudXWgZZN{[XluIFfJOVA:OzgQvF2= NULHfWF4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5PFYxPjJpPkOwPVg3ODZ{PD;hQi=>
MDA-MB-231 MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH7k[|c4OiCqcoO= NXroeo55T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWJtfWViYYPzZZktKEeLNUC9OFIvQM7:TR?= NYThO5JGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5PFYxPjJpPkOwPVg3ODZ{PD;hQi=>
HeLa NFjh[2tEgXSxdH;4bYNqfHliYYPzZZk> NXvIXGNWPTBidV2= NWjCRpV7PzJiaILz Mn\jR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYYSgOVAhfU1ibXXhd5Vz\WRiYX\0[ZIhPzJiaILzJIJ6KEOFS{igZZN{[Xl? M1TqelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUG3OVE3Lz5|MUGxO|UyPjxxYU6=
MCF7 NFPpVVNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWWxOUB2VQ>? NHPwZoU4OiCqcoO= MWnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNR2Y4KGOnbHzzJIF1KDF3IIXNJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDBcIFu[XKEbIXlJIF{e2G7 NUfFUWJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GxOFQ5OTRpPkOxNVQ1QDF2PD;hQi=>
Neuro2a M3Lq[GZ2dmO2aX;uJIF{e2G7 NGflT2cxNjJidH:gNkB2VQ>? NV32eIpyOjRiaILz NWHHTIJ{UW6mdXP0bY9vKG:oIH7leZJqfGVib4X0[5Jwf3SqIHnuJI1wfXOnIF7leZJwOmFiY3XscJMh[XRiMD6yJJRwKDJidV2gcYVie3W{ZXSgZYZ1\XJiMkSgbJJ{KGK7IH3pZ5Jwe2OxcHnjJIFv[Wy7c3nz M2n4OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUS0PFE1Lz5|MUG0OFgyPDxxYU6=
HCT116 NVrlSZdlTnWwY4Tpc44h[XO|YYm= NUfnTnhxOjVidV2= MmXWOkBpenN? NGrFV|dKdmirYnn0bY9vKG:oIGPJVnQzKGmwIHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjbIDoZU11fWK3bHnuJIFk\XS7bHH0bY9vKGG2IEK1JJVOKGmwY4XiZZRm\CCob4KgOkBpenNiYomgSGFRUSC|dHHpcolv\y2kYYPl[EBt[XOncjDzZ4FvdmmwZzDjc45nd2OjbDDtbYNzd3Olb4DpZ{BidmGueYPpdy=> M3ridFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUi2NFYzLz5|MEm4OlA3OjxxYU6=
HCT116 NGn1Z5FHfW6ldHnvckBie3OjeR?= NGDleIY2OCC3TR?= M1HhelYhcHK| NXzGOW1uUW6qaXLpeIlwdiCxZjDTTXJVOiCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iYXzwbIEufHWkdXzpckBi[2W2eXzheIlwdiCjdDC1NEB2VSCrbnP1ZoF1\WRiZn;yJFYhcHK|IHL5JGRCWElic4ThbY5qdmdvYnHz[YQhdGG|ZYKgd4Nidm6rbnegZ49v\m:lYXygcYlkem:|Y3;wbYMh[W6jbInzbZM> M2m5Z|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUi2NFYzLz5|MEm4OlA3OjxxYU6=
In vivo The anticancer effect of TM correlates with its ability to decrease c-Myc level. TM has limited effects on non-cancerous cells and tumor-free mice[1].

Protocol (from reference)

Cell Research:[1]
  • Cell lines: breast cancer cell lines MCF-7
  • Concentrations: 1, 5, 10, 25, 50 μM
  • Incubation Time: 6 h
  • Method: Human MCF-7 cells are grown in DMEM media contained 10% (vol/vol) heat-inactivated fetal bovine serum and 1% penicillin-streptomycin and treated with in the presence of 200 nM TSA for 6 hr. The acetylation level of p53 protein is determined by western blot using anti-acetyl-p53 (K382) antibody. β-actin serves as a loading control.
Animal Research:[1]
  • Animal Models: Mouse xenograft model
  • Dosages: 1.5 mg/50 μL (IP); 0.75 mg/50 μL (IT)
  • Administration: intraperitoneal (IP) or intra-tumor (IT) injections

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 581.85
Formula

C34H51N3O3S

CAS No. 1429749-41-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCCCCCCCCCCCCC(=S)NCCCCC(C(=O)NC1=CC=CC=C1)NC(=O)OCC2=CC=CC=C2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05134740 Recruiting Biological: TAA-specific CTLs Hodgkins Lymphoma|Non Hodgkins Lymphoma Baylor College of Medicine|Center for Cell and Gene Therapy Baylor College of Medicine September 4 2022 Phase 1
NCT04684121 Not yet recruiting Drug: Granexin® gel (200 μM)|Drug: Vehicle gel Second Degree Burn|Thermal Burn Xequel Bio Inc.|United States Department of Defense August 1 2022 Phase 2
NCT05449431 Not yet recruiting Other: TLC1_TM6|Other: TM6_TLC1 Idiopathic Pulmonary Fibrosis Groupe Hospitalier Paris Saint Joseph July 4 2022 Not Applicable
NCT05452018 Not yet recruiting Other: Intervention group Healthy Volunteers University Hospital Grenoble|Clinical Investigation Centre for Innovative Technology Network|GIPSA-LAB July 2022 Not Applicable

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Thiomyristoyl | Thiomyristoyl supplier | purchase Thiomyristoyl | Thiomyristoyl cost | Thiomyristoyl manufacturer | order Thiomyristoyl | Thiomyristoyl distributor